Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion (Q56904375)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion	article

Statements

scholarly article

0 references

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

6

object named as

Paul Emery

0 references

Stanley B Cohen

7

object named as

Stanley Cohen

0 references

author name string

Larry W Moreland

1

0 references

Rieke Alten

2

0 references

Filip Van den Bosch

3

0 references

Thierry Appelboom

4

0 references

Marc Leon

5

0 references

Michael Luggen

8

0 references

William Shergy

9

0 references

Isaac Nuamah

10

0 references

Jean-Claude Becker

11

0 references

language of work or name

0 references

publication date

June 2002

0 references

Arthritis and Rheumatism

0 references

46

0 references

1470-9

0 references

6

0 references

Predominantly T-Cell Infiltrate in Rheumatoid Synovial Membranes

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

Efficacy of total lymphoid irradiation in intractable rheumatoid arthritis. A double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

B70 antigen is a second ligand for CTLA-4 and CD28.

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

CD40-CD40 ligand interaction in autoimmune disease

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

Role of antigen-presenting cells in mediating tolerance and autoimmunity

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

Treatment of murine lupus with CTLA4Ig

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

CTLA-4 is a second receptor for the B cell activation antigen B7

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study

1 reference

https://api.crossref.org/works/10.1002%2FART.10294

21 January 2018

Identifiers

10.1002/ART.10294

0 references

Dimensions Publication ID

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56904375&oldid=1487521017"